Samotolisib — drug · CancerIndex

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Phase2	Phase 2	3	1	13	0	—	—	Jul 31, 2012
Malignant Central Nervous System Neoplasm	Phase2	Phase 2	1	0	2	0	—	—	Jul 31, 2017
Malignant Liver Neoplasm	Phase2	Phase 2	1	0	2	0	—	—	Jul 31, 2017
Malignant Uterine Corpus Neoplasm	Phase2	Phase 2	1	1	2

Curated evidence

Clinical evidence (1)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
BAP1 Mutation + NF2 Mutation + SETD2 MutationBAP1 SETD2

Clinical trials

Trials with this intervention (14)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–14 of 14 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03155620	Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)	active not recruiting	Phase 2	1,377	National Cancer Institute (NCI)NIH	4	Jul 24, 2026	clinicaltrials
NCT02632994	Master Rollover Protocol for Continued Safety Assessment of Study Drug